Provided by Tiger Fintech (Singapore) Pte. Ltd.

MiNK Therapeutics, Inc.

8.49
+0.50806.37%
Post-market: 8.490.00000.00%19:17 EDT
Volume:2.52K
Turnover:20.87K
Market Cap:33.64M
PE:-2.25
High:8.49
Open:8.37
Low:8.18
Close:7.98
Loading ...

Company Profile

Company Name:
MiNK Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
31
Office Location:
149 Fifth Avenue,Suite 500,New York,New York,United States
Zip Code:
10010
Fax:
- -
Introduction:
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Directors

Name
Position
Garo H. Armen
Chairman of the Board
Jennifer S. Buell
President, Chief Executive Officer and Director
Barbara Ryan
Director
Brian Corvese
Director
John Baldoni
Director
Peter Behner
Director
Ulf Wiinberg
Director
Walter Flamenbaum
Director

Shareholders

Name
Position
Jennifer S. Buell
President, Chief Executive Officer and Director
Christine M. Klaskin
Treasurer
Marc van Dijk
Chief Technology Officer